The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications
Open accessAbstract
Cushing's syndrome is associated with increased mortality, mainly due to cardiovascular complications, which are sustained by the common development of systemic arterial hypertension and metabolic syndrome, which partially persist after the disease remission. Cardiovascular diseases and hypertension associated with endogenous hypercortisolism reveal underexplored peculiarities. The use of exogenous corticosteroids also impacts on hypertension and cardiovascular system, especially after prolonged treatment. The mechanisms involved in the development of hypertension differ, whether glucocorticoid excess is acute or chronic, and the source endogenous or exogenous, introducing inconsistencies among published studies. The pleiotropic effects of glucocorticoids and the overlap of the several regulatory mechanisms controlling blood pressure suggest that a rigorous comparison of in-vivo and in-vitro studies is necessary to draw reliable conclusions. This review, developed during the first 'Altogether to Beat Cushing's syndrome' workshop held in Capri in 2012, evaluates the most important peculiarities of hypertension associated with CS, with a particular focus on its pathophysiology. A critical appraisal of most significant animal and human studies is compared with a systematic review of the few available clinical trials. A special attention is dedicated to the description of the clinical features and cardiovascular damage secondary to glucocorticoid excess. On the basis of the consensus reached during the workshop, a pathophysiology-oriented therapeutic algorithm has been developed and it could serve as a first attempt to rationalize the treatment of hypertension in Cushing's syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111 · cited 1×
“Eplerenone could be used as an alternative to spironolactone, especially in men [138]; however, it is not available as a subsidized medication in several countries, it is expensive compared to amiloride and spironolactone and, therefore, could suffer compliance in medium to longterm treatment.”
BackgroundThe Effects of Diet on Inflammation
Giugliano, D., Ceriello, A., & Esposito, K. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.03.052 · Cited by 842
A 12-month phase 3 study of pasireotide in Cushing's disease
Colao, A., Petersenn, S., Newell-Price, J., Findling, J. W., Gu, F., Maldonado, M., Schoenherr, U., Dipl.-Biol., Mills, D., Salgado, L. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105743 · Cited by 628
Self-citationFleseriu, M., Biller, B. M. K., Findling, J. W., Molitch, M. E., Schteingart, D. E., Gross, C., on behalf of the SEISMIC Study Investigators, The SEISMIC Study Investigators include, Auchus, R., Bailey, T., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3350 · Cited by 479 · cited 2×
“Finally, the results of the recent multicenter, randomized controlled clinical trials exploring the effects of pasireotide [126] and LCI699 [128] or mifrepistone [130] allow a more precise estimate of how”
BackgroundResultMultisystem morbidity and mortality in Cushing’s syndrome: a cohort study
Dekkers, O. M., Horváth-Puhó, E., Jørgensen, J. O. L., Cannegieter, S. C., Ehrenstein, V., Vandenbroucke, J. P., Pereira, A. M., & Sørensen, H. T. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3582 · Cited by 419
Valassi, E., Santos, A., Yaneva, M., Tóth, M., Strasburger, C. J., Chanson, P., Wass, J. A. H., Chabre, O., Pfeifer, M., Feelders, R. A., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0272 · Cited by 402
ARMC5 Mutations in Macronodular Adrenal Hyperplasia with Cushing's Syndrome
Assié, G., Libé, R., Espiard, S., Rizk-Rabin, M., Guimier, A., Luscap, W., Barreau, O., Lefèvre, L., Sibony, M., Guignat, L., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304603 · Cited by 395
Faggiano, A., Pivonello, R., Spiezia, S., De Martino, M. C., Filippella, M., Di Somma, C., Lombardi, G., & Colao, A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021558 · Cited by 358
Self-citation
Research works printed but not linked: 121
- Graversen, 2012, Mortality in Cushings syndrome: a systematic review and meta-analysis., Eur J Intern Med, 23, 278, 10.1016/j.ejim.2011.10.013 · DOI
- Lambert, 2013, Predictors of mortality and long-term outcomes in treated Cushings disease: a study of 346 patients., J Clin Endocrinol Metab, 98, 1022, 10.1210/jc.2012-2893 · DOI · Paper page
- Bertoia, 2012, Implications of new hypertension guidelines in the United States., Hypertension, 60, 639, 10.1161/HYPERTENSIONAHA.112.193714 · DOI
- Imai, 1988, Altered circadian blood pressure rhythm in patients with Cushings syndrome., Hypertension, 12, 11, 10.1161/01.HYP.12.1.11 · DOI · Paper page
- Pecori, 2007, Circadian blood pressure profile in patients with active Cushings disease and after long-term cure., Horm Metab Res, 39, 908, 10.1055/s-2007-992813 · DOI
- Walker, 1993, Deficient inactivation of cortisol by 11 beta-hydroxysteroid dehydrogenase in essential hypertension., Clin Endocrinol (Oxf), 39, 221, 10.1111/j.1365-2265.1993.tb01778.x · DOI · Paper page
- Watt, 1992, Abnormalities of glucocorticoid metabolism and the renin-angiotensin system: a four-corners approach to the identification of genetic determinants of blood pressure., J Hypertens, 10, 473, 10.1097/00004872-199205000-00011 · DOI · Paper page
- Van Staa, 2000, Use of oral corticosteroids in the United Kingdom., QJM, 93, 105, 10.1093/qjmed/93.2.105 · DOI · Paper page
- Imai, 1989, Exogenous glucocorticoid eliminates or reverses circadian blood pressure variations., J Hypertens, 7, 113, 10.1097/00004872-198902000-00006 · DOI
- Wei, 2004, Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease., Ann Intern Med, 141, 764, 10.7326/0003-4819-141-10-200411160-00007 · DOI · Paper page
- Souverein, 2004, Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study., Heart, 90, 859, 10.1136/hrt.2003.020180 · DOI · Paper page
- Devoe, 1997, Long-term outcome in children and adolescents after transsphenoidal surgery for Cushings disease., J Clin Endocrinol Metab, 82, 3196
- Lodish, 2009, Blood pressure in pediatric patients with Cushing syndrome., J Clin Endocrinol Metab, 94, 2002, 10.1210/jc.2008-2694 · DOI
- Feelders, 2012, The burden of Cushings disease: clinical and health-related quality of life aspects., Eur J Endocrinol, 167, 311, 10.1530/EJE-11-1095 · DOI · Paper page
- Rossi, 2011, Drug-related hypertension and resistance to antihypertensive treatment: a call for action., J Hypertens, 29, 2295, 10.1097/HJH.0b013e32834c465d · DOI
- Hammer, 2006, Cortisol metabolism in hypertension., Best Pract Res Clin Endocrinol Metab, 20, 337, 10.1016/j.beem.2006.07.001 · DOI
- Magiakou, 1997, Blood pressure in children and adolescents with Cushings syndrome before and after surgical care., J Clin Endocrinol Metab, 82, 1734
- Dias, 2006, The discriminatory value of the low-dose dexamethasone suppression test in the investigation of paediatric Cushings syndrome., Horm Res, 65, 159
- Storr, 2004, Prepubertal Cushings disease is more common in males, but there is no increase in severity at diagnosis., J Clin Endocrinol Metab, 89, 3818, 10.1210/jc.2003-031531 · DOI
- Ulick, 1992, Cortisol inactivation overload: a mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome., J Clin Endocrinol Metab, 74, 963
- Saruta, 1986, Multiple factors contribute to the pathogenesis of hypertension in Cushings syndrome., J Clin Endocrinol Metab, 62, 275, 10.1210/jcem-62-2-275 · DOI · Paper page
- Ritchie, 1990, Studies on the pathogenesis of hypertension in Cushings disease and acromegaly., Q J Med, 76, 855
- Yasuda, 1994, Exaggerated blood pressure response to angiotensin II in patients with Cushings syndrome due to adrenocortical adenoma., Eur J Endocrinol, 131, 582, 10.1530/eje.0.1310582 · DOI
- Fuller, 2005, Mechanisms of mineralocorticoid action., Hypertension, 46, 1227, 10.1161/01.HYP.0000193502.77417.17 · DOI · Paper page
- Stewart, 1995, 11 beta-Hydroxysteroid dehydrogenase activity in Cushings syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome., J Clin Endocrinol Metab, 80, 3617
- Isidori, 2006, The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up., J Clin Endocrinol Metab, 91, 371, 10.1210/jc.2005-1542 · DOI · Paper page
- Whitworth, 1989, The hypertensive effect of synthetic glucocorticoids in man: role of sodium and volume., J Hypertens, 7, 537, 10.1097/00004872-198907000-00005 · DOI
- Williamson, 1996, Dose-response relationships and mineralocorticoid activity in cortisol-induced hypertension in humans., J Hypertens Suppl, 14, S37
- Bailey, 2009, Mineralocorticoid and glucocorticoid receptors stimulate epithelial sodium channel activity in a mouse model of Cushing syndrome., Hypertension, 54, 890, 10.1161/HYPERTENSIONAHA.109.134973 · DOI
- Nieman, 1985, Successful treatment of Cushings syndrome with the glucocorticoid antagonist RU 486., J Clin Endocrinol Metab, 61, 536, 10.1210/jcem-61-3-536 · DOI · Paper page
- McMahon, 2001, Recent studies with eplerenone, a novel selective aldosterone receptor antagonist., Curr Opin Pharmacol, 1, 190, 10.1016/S1471-4892(01)00022-4 · doi:10.1016/s1471-4892(01)00022-4
- Rickard, 2012, Cardiomyocyte mineralocorticoid receptors are essential for deoxycorticosteronesalt-mediated inflammation and cardiac fibrosis., Hypertension, 60, 1443, 10.1161/HYPERTENSIONAHA.112.203158 · DOI
- Nagata, 2006, Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats., Hypertension, 47, 656, 10.1161/01.HYP.0000203772.78696.67 · DOI · Paper page
- Mannelli, 1994, Adrenal medulla secretion in Cushings syndrome., J Clin Endocrinol Metab, 78, 1331
- Heaney, 1999, Increased pressor response to noradrenaline in pituitary dependent Cushings syndrome., Clin Endocrinol (Oxf), 51, 293, 10.1046/j.1365-2265.1999.00766.x · DOI
- McKnight, 1995, Blood pressure responses to phenylephrine infusions in subjects with Cushings syndrome., J Hum Hypertens, 9, 855
- Jyotsna, 2011, Effect of Cushings syndrome: endogenous hypercortisolemia on cardiovascular autonomic functions., Auton Neurosci, 160, 99, 10.1016/j.autneu.2010.11.007 · DOI
- Ruschitzka, 2001, Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition: role of nitric oxide., Circulation, 103, 3129, 10.1161/01.CIR.103.25.3129 · DOI
- Kirilov, 2003, Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushings syndrome., Eur J Endocrinol, 149, 549, 10.1530/eje.0.1490549 · DOI
- Kelly, 2000, Role of erythropoietin in cortisol-induced hypertension., J Hum Hypertens, 14, 195, 10.1038/sj.jhh.1000959 · DOI
- Smith, 1994, Regulation of sodium-calcium exchanger by glucocorticoids and growth factors in vascular smooth muscle., J Biol Chem, 269, 27527, 10.1016/S0021-9258(18)47016-0 · doi:10.1016/s0021-9258(18)47016-0
- Radomski, 1990, Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells., Proc Natl Acad Sci U S A, 87, 10043, 10.1073/pnas.87.24.10043 · DOI · Paper page
- Wallerath, 1999, Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension., Proc Natl Acad Sci U S A, 96, 13357, 10.1073/pnas.96.23.13357 · DOI · Paper page
- Simmons, 1996, Glucocorticoids regulate inducible nitric oxide synthase by inhibiting tetrahydrobiopterin synthesis and L-arginine transport., J Biol Chem, 271, 23928, 10.1074/jbc.271.39.23928 · DOI · Paper page
- Kelly, 1998, The nitric oxide system and cortisol-induced hypertension in humans., Clin Exp Pharmacol Physiol, 25, 945, 10.1111/j.1440-1681.1998.tb02349.x · DOI
- Rizzoni, 2006, Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronism., J Clin Endocrinol Metab, 91, 2638, 10.1210/jc.2006-0101 · DOI
- Limbourg, 2002, Rapid nontranscriptional activation of endothelial nitric oxide synthase mediates increased cerebral blood flow and stroke protection by corticosteroids., J Clin Invest, 110, 1729, 10.1172/JCI0215481 · doi:10.1172/jci0215481 · Paper page
- Serarslan, 2010, Protective effects of tadalafil on experimental spinal cord injury in rats., J Clin Neurosci, 17, 349, 10.1016/j.jocn.2009.03.036 · doi:10.1016/j.jocn.2009.03.036
- Colao, 2012, Chronic Inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging., Circulation, 125, 2323, 10.1161/CIRCULATIONAHA.111.063412 · DOI · Paper page
- Knoepfelmacher, 1998, Effect of corticotrophin-releasing hormone on arginine vasopressin and atrial natriuretic factor in patients with Cushings disease., Clin Endocrinol (Oxf), 49, 77, 10.1046/j.1365-2265.1998.00479.x · DOI
- Knoepfelmacher, 1997, Resistance to vasopressin action on the kidney in patients with Cushings disease., Eur J Endocrinol, 137, 162, 10.1530/eje.0.1370162 · DOI
- Yamaji, 1988, Plasma levels of atrial natriuretic hormone in Cushings syndrome., J Clin Endocrinol Metab, 67, 348, 10.1210/jcem-67-2-348 · doi:10.1210/jcem-67-2-348
- Sala, 2001, Blunted vascular and renal effects of exogenous atrial natriuretic peptide in patients with cushings disease., J Clin Endocrinol Metab, 86, 1957
- Yasunari, 1990, Glucocorticoids and atrial natriuretic factor receptors on vascular smooth muscle., Hypertension, 16, 581, 10.1161/01.HYP.16.5.581 · DOI
- Fujio, 1989, Cardiovascular, renal and endocrine effects of alpha-human atrial natriuretic peptide in patients with Cushings syndrome and primary aldosteronism., J Hypertens, 7, 653, 10.1097/00004872-198908000-00009 · doi:10.1097/00004872-198908000-00009
- Axelrod, 1983, Inhibition of prostacyclin production mediates permissive effect of glucocorticoids on vascular tone. Perturbations of this mechanism contribute to pathogenesis of Cushings syndrome and Addisons disease., Lancet, 1, 904, 10.1016/S0140-6736(83)91330-2 · DOI
- Shimamoto, 1995, Significance of renal kininases in patients with Cushings syndrome., Clin Exp Hypertens, 17, 1173, 10.3109/10641969509037402 · DOI
- van Raalte, 2009, Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options Eur J Clin I, nvest, 39, 81
- Giordano, 2012, Glucose metabolism in patients with subclinical Cushings syndrome., Endocrine, 41, 415, 10.1007/s12020-012-9628-9 · DOI
- Huang, 2002, Regulation of pyruvate dehydrogenase kinase expression by peroxisome proliferator-activated receptor-alpha ligands, glucocorticoids, and insulin., Diabetes, 51, 276, 10.2337/diabetes.51.2.276 · DOI · Paper page
- Patel, 2011, LXRbeta is required for glucocorticoid-induced hyperglycemia and hepatosteatosis in mice., J Clin Invest, 121, 431, 10.1172/JCI41681 · DOI
- Albiger, 2006, Patients with Cushings syndrome have increased intimal media thickness at different vascular levels: comparison with a population matched for similar cardiovascular risk factors., Horm Metab Res, 38, 405, 10.1055/s-2006-944545 · DOI
- Giordano, 2014, Is diabetes in Cushings syndrome only a consequence of hypercortisolism Eur J E, ndocrinol, 170, 311
- Colao, 1999, Persistence of increased cardiovascular risk in patients with Cushings disease after five years of successful cure., J Clin Endocrinol Metab, 84, 2664
- Zacharieva, 2004, Vascular endothelial growth factor (VEGF), prostaglandin E2(PGE2) and active renin in hypertension of adrenal origin., J Endocrinol Invest, 27, 742, 10.1007/BF03347516 · doi:10.1007/bf03347516
- Bender, 2013, Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease D, iabetes, 62, 313
- Gatenby, 2010, The role of IGF-1 resistance in obesity and type 2 diabetes-mellitus-related insulin resistance and vascular disease., Expert Opin Ther Targets, 14, 1333, 10.1517/14728222.2010.528930 · DOI
- Parati, 2012, Position paper on the management of patients with obstructive sleep apnea and hypertension: joint recommendations by the European Society of Hypertension, by the European Respiratory Society and by the members of European COST (COoperation in Scientific and Technological research) ACTION B26 on obstructive sleep apnea., J Hypertens, 30, 633, 10.1097/HJH.0b013e328350e53b · DOI · Paper page
- Bottini, 2003, Sleep apnea syndrome in endocrine diseases., Respiration, 70, 320, 10.1159/000072019 · DOI
- Shipley, 1992, Sleep architecture and sleep apnea in patients with Cushings disease., Sleep, 15, 514, 10.1093/sleep/15.6.514 · DOI
- Venkatram, 2014, Unusual triad of obstructive sleep apnea, uncontrolled hypertension, and severe hypokalemia due to ectopic adrenocorticotropic secretion., J Bronchology Interv Pulmonol, 21, 158, 10.1097/LBR.0000000000000060 · doi:10.1097/lbr.0000000000000060
- Zanchetti, 2012, What should be learnt about the management of obstructive sleep apnea in hypertension J H, ypertens, 30, 669, 10.1097/HJH.0b013e328351b988 · DOI
- Lewington, 2002, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies., Lancet, 360, 1903, 10.1016/S0140-6736(02)11911-8 · DOI · Paper page
- Etxabe, 1994, Morbidity and mortality in Cushings disease: an epidemiological approach., Clin Endocrinol (Oxf), 40, 479, 10.1111/j.1365-2265.1994.tb02486.x · DOI · Paper page
- Clayton, 2011, Mortality and morbidity in Cushings disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature., J Clin Endocrinol Metab, 96, 632, 10.1210/jc.2010-1942 · DOI · Paper page
- Coylewright, 2008, Menopause and hypertension: an age-old debate., Hypertension, 51, 952, 10.1161/HYPERTENSIONAHA.107.105742 · DOI · Paper page
- Zacharieva, 2004, Circadian blood pressure profile in patients with Cushings syndrome before and after treatment., J Endocrinol Invest, 27, 924, 10.1007/BF03347534 · doi:10.1007/bf03347534
- Gagliardi, 2014, ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia., J Clin Endocrinol Metab, 99, E1784, 10.1210/jc.2014-1265 · DOI · Paper page
- Varughese, 2014, Hypercortisolism in obesity-associated hypertension., Curr Hypertens Rep, 16, 443, 10.1007/s11906-014-0443-y · DOI
- Muiesan, 2003, Left ventricular structural and functional characteristics in Cushings syndrome., J Am Coll Cardiol, 41, 2275, 10.1016/S0735-1097(03)00493-5 · DOI · Paper page
- Toja, 2012, Clinical relevance of cardiac structure and function abnormalities in patients with Cushings syndrome before and after cure., Clin Endocrinol (Oxf), 76, 332, 10.1111/j.1365-2265.2011.04206.x · DOI
- Ainscough, 2009, Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction., Cardiovasc Res, 81, 592, 10.1093/cvr/cvn230 · DOI
- Mihailidou, 2009, Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction., Hypertension, 54, 1306, 10.1161/HYPERTENSIONAHA.109.136242 · DOI · Paper page
- Yiu, 2012, Increased myocardial fibrosis and left ventricular dysfunction in Cushings syndrome., Eur J Endocrinol, 166, 27, 10.1530/EJE-11-0601 · DOI
- Alexandraki, 2011, Specific electrocardiographic features associated with Cushings disease., Clin Endocrinol (Oxf), 74, 558, 10.1111/j.1365-2265.2011.03975.x · DOI
- Fallo, 2009, Cardiovascular autonomic function in Cushings syndrome., J Endocrinol Invest, 32, 41, 10.1007/BF03345677 · DOI
- De Leo, 2010, Cardiovascular disease in Cushings syndrome: heart versus vasculature., Neuroendocrinology, 92, 50, 10.1159/000318566 · DOI
- Akaza, 2010, Endothelial dysfunction aassociated with hypercortisolism is reversible in Cushings syndrome., Endocr J, 57, 245, 10.1507/endocrj.K09E-260 · DOI
- Baykan, 2007, Impairment of flow-mediated vasodilatation of brachial artery in patients with Cushings Syndrome., Endocrine, 31, 300, 10.1007/s12020-007-0033-8 · DOI
- Prazny, 2008, Impaired microvascular reactivity and endothelial function in patients with Cushings syndrome: influence of arterial hypertension., Physiol Res, 57, 13, 10.33549/physiolres.931126 · DOI
- Molnar, 2008, Glucocorticoid-related signaling effects in vascular smooth muscle cells., Hypertension, 51, 1372, 10.1161/HYPERTENSIONAHA.107.105718 · DOI
- van den Meiracker, 2008, Corticosteroid-dependent, aldosterone-independent mineralocorticoid-receptor activation in the heart., J Hypertens, 26, 1307, 10.1097/HJH.0b013e328305e195 · DOI
- Koh, 2000, Increased urinary albumin excretion in Cushings syndrome: remission after correction of hypercortisolaemia., Clin Endocrinol (Oxf), 52, 349, 10.1046/j.1365-2265.2000.00917.x · DOI
- Faggiano, 2002, Evaluation of circulating levels and renal clearance of natural amino acids in patients with Cushings disease., J Endocrinol Invest, 25, 142, 10.1007/BF03343978 · DOI
- Faggiano, 2003, Nephrolithiasis in Cushings disease: prevalence, etiopathogenesis, and modification after disease cure., J Clin Endocrinol Metab, 88, 2076, 10.1210/jc.2002-021494 · DOI
- Biller, 2009, The Network for the Enhancement of Endocrinology and Oncology Knowledge: a case-based consideration of current practice in Cushings disease and acromegaly., Best Pract Res Clin Endocrinol Metab, 23, S1, 10.1016/S1521-690X(09)00149-3 · DOI
- Hammer, 2004, Transsphenoidal microsurgery for Cushings disease: initial outcome and long-term results., J Clin Endocrinol Metab, 89, 6348, 10.1210/jc.2003-032180 · DOI · Paper page
- Lindholm, 2001, Incidence and late prognosis of cushings syndrome: a population-based study., J Clin Endocrinol Metab, 86, 117
- Chow, 2008, Bilateral laparoscopic adrenalectomy for corticotrophin-dependent Cushings syndrome: a review of the Mayo Clinic experience., Clin Endocrinol (Oxf), 68, 513, 10.1111/j.1365-2265.2007.03082.x · DOI
- Bassareo, 2010, Increased arterial rigidity in children affected by Cushings syndrome after successful surgical cure., Cardiol Young, 20, 610, 10.1017/S1047951110000727 · DOI
- Nieman, 2002, Medical therapy of Cushings disease., Pituitary, 5, 77, 10.1023/A:1022308429992 · DOI · Paper page
- Pecori Giraldi, 2012, Potential role for retinoic acid in patients with Cushings disease., J Clin Endocrinol Metab, 97, 3577, 10.1210/jc.2012-2328 · DOI
- Donadille, 2010, Management of Cushings syndrome due to ectopic adrenocorticotropin secretion with 1,ortho-1, para-dichloro-diphenyl-dichloro-ethane: findings in 23 patients from a single center., J Clin Endocrinol Metab, 95, 537, 10.1210/jc.2009-1317 · DOI
- Pivonello, 2009, The medical treatment of Cushings disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery., J Clin Endocrinol Metab, 94, 223, 10.1210/jc.2008-1533 · DOI · Paper page
- Pivonello, 2014, Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushings disease: results from a Phase III study., Clin Endocrinol (Oxf), 81, 408, 10.1111/cen.12431 · DOI
- Feelders, 2010, Pasireotide alone or with cabergoline and ketoconazole in Cushings disease., N Engl J Med, 362, 1846, 10.1056/NEJMc1000094 · DOI · Paper page
- Bertagna, 2014, LCI699, a potent 11beta-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushings disease: results from a multicenter, proof-of-concept study., J Clin Endocrinol Metab, 99, 1375, 10.1210/jc.2013-2117 · DOI · Paper page
- Castinetti, 2012, The use of the glucocorticoid receptor antagonist mifepristone in Cushings syndrome., Curr Opin Endocrinol Diabetes Obes, 19, 295, 10.1097/MED.0b013e32835430bf · DOI
- Fallo, 1993, Response of hypertension to conventional antihypertensive treatment andor steroidogenesis inhibitors in Cushings syndrome., J Intern Med, 234, 595, 10.1111/j.1365-2796.1993.tb01018.x · DOI
- Mancia, 2014, Target blood pressure in elderly hypertensive patients and in patients with diabetes mellitus., J Hypertens, 32, 1551, 10.1097/HJH.0000000000000275 · DOI
- da MF, Murray, 2011, Overt immune dysfunction after Cushings syndrome remission: a consecutive case series and review of the literature., J Clin Endocrinol Metab, 96, E1670, 10.1210/jc.2011-1317 · DOI
- Zanchetti, 2002, Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial., Circulation, 106, 2422, 10.1161/01.CIR.0000039288.86470.DD · DOI · Paper page
- Thompson, 2011, Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis., J Am Med Assoc, 305, 913, 10.1001/jama.2011.250 · DOI · Paper page
- Greenberg, 2000, Diuretic complications., Am J Med Sci, 319, 10, 10.1016/S0002-9629(15)40676-7 · DOI
- Mason, 2005, The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension., J Hypertens, 23, 1777, 10.1097/01.hjh.0000177537.91527.09 · DOI
- Wolfgram, 2013, Hydrochlorothiazide compared to chlorthalidone in reduction of urinary calcium in patients with kidney stones., Urolithiasis, 41, 315, 10.1007/s00240-013-0568-5 · doi:10.1007/s00240-013-0568-5
- Vigen, 2011, Thiazides diuretics in the treatment of nephrolithiasis: are we using them in an evidence-based fashion Int Urol N, ephrol, 43, 813
- Chapman, 2008, Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial., Circulation, 118, 42, 10.1161/CIRCULATIONAHA.107.737957 · DOI
- Dahlof, 2005, Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial., Lancet, 366, 895, 10.1016/S0140-6736(05)67185-1 · DOI · Paper page
- Mancia, 2006, New-onset diabetes and antihypertensive drugs., J Hypertens, 24, 3, 10.1097/01.hjh.0000194119.42722.21 · DOI · Paper page
- Laurent, 2012, New drugs, procedures, and devices for hypertension., Lancet, 380, 591, 10.1016/S0140-6736(12)60825-3 · DOI
Cited by
Complications of Cushing's syndrome: state of the art
Pivonello, R., Isidori, A. M., De Martino, M. C., Newell-Price, J., Biller, B. M. K., & Colao, A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00086-3 · Cited by 641
Self-citationThe Treatment of Cushing's Disease
Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 465
Self-citationCushing’s Syndrome: Screening and Diagnosis
Ceccato, F., & Boscaro, M. (2016) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-016-0153-4 · Cited by 70
Factors predicting long-term comorbidities in patients with Cushing's syndrome in remission
Schernthaner-Reiter, M. H., Siess, C., Gessl, A., Scheuba, C., Wolfsberger, S., Riss, P., Knosp, E., Luger, A., & Vila, G. (2019) · Endocrine · doi:10.1007/s12020-018-1819-6 · Cited by 60
Kannankeril, J., Carroll, T., Findling, J. W., Javorsky, B., Gunsolus, I. L., Phillips, J., & Raff, H. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa107 · Cited by 36
“Neoplastic hypercortisolism is often responsible for cardiometabolic problems, including obesity, diabetes, hypertension, and low bone density, as well as significant neurocognitive and neuropsychiatric challenges [1-16].”
Background
Metadata
- Authors
- Isidori, A. M., Graziadio, C., Paragliola, R. M., Cozzolino, A., Ambrogio, A. G., Colao, A., Corsello, S. M., & Pivonello, R.
- Venue
- Journal of Hypertension
- Published
- 2015-01
- Volume
- 33
- Issue
- 1
- Pages
- 44-60
- ISSN
- 0263-6352 (ISSN-L)
- OpenAlex
- W1979363038
- Cited by
- 185
- References
- 24
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications. https://app.cochat.ai/papers/10.1097/hjh.0000000000000415
- The paper
- Isidori, A. M., Graziadio, C., Paragliola, R. M., Cozzolino, A., Ambrogio, A. G., Colao, A., Corsello, S. M., & Pivonello, R. (2015). The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications. Journal of Hypertension. https://doi.org/10.1097/hjh.0000000000000415
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.